Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.
Feature|Articles|September 18, 2026
Vitamin K Refusals Are Rising: What Payers Need to Know
Author(s)Sabrina McCrear
Fact checked by: Laura Joszt, MA, William Schaffner, MD
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Advertisement
Advertisement
Vitamin K shot refusals among newborns in the US have risen 77%, from 2.92% in 2017 to 5.18% in 2024, leading clinicians interviewed for this piece to believe broader
Related to this article
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Single-discipline autism guidelines that fail Institute of Medicine standards risk omitting critical developmental domains, potentially distorting care coverage and clinical decisions for children with autism.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Claims data also tied the combination to better adherence and fewer hospital admissions, including in bipolar I disorder, vs olanzapine alone.
Advertisement
Advertisement